Literature DB >> 29567032

The future control of rotavirus disease: Can live oral vaccines alone solve the rotavirus problem?

Roger I Glass1, Baoming Jiang2, Umesh Parashar2.   

Abstract

Live oral rotavirus (RV) vaccines used worldwide are most effective in reducing diarrheal hospitalizations from RV in high income countries and least effective in low income countries where RV remains a prime cause of death in children. Research has failed to fully explain the reason for this difference of efficacy for RV vaccines, an observation made with other live oral vaccines for polio, cholera and typhoid fever. Use of parenteral vaccines have been successful in overcoming this problem for both polio and typhoid and parenteral RV vaccines are now in development. This approach should be pursued for rotavirus vaccine as well because in low income countries where oral RV vaccines have been introduced and are only partially effective, RV remains the most common cause of diarrhea in children under 5 years. The ultimate control of RV diarrheal will likely require both oral and parenteral vaccines. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29567032     DOI: 10.1016/j.vaccine.2018.03.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Winning the Battle Against Rotavirus Diarrhea…One Step at a Time.

Authors:  Michelle J Groome; Roger I Glass
Journal:  J Infect Dis       Date:  2020-10-13       Impact factor: 5.226

2.  Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi.

Authors:  Virginia E Pitzer; Aisleen Bennett; Naor Bar-Zeev; Khuzwayo C Jere; Benjamin A Lopman; Joseph A Lewnard; Umesh D Parashar; Nigel A Cunliffe
Journal:  Sci Transl Med       Date:  2019-08-14       Impact factor: 17.956

Review 3.  The Rotavirus Vaccine Landscape, an Update.

Authors:  Roberto Cárcamo-Calvo; Carlos Muñoz; Javier Buesa; Jesús Rodríguez-Díaz; Roberto Gozalbo-Rovira
Journal:  Pathogens       Date:  2021-04-26

4.  Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.

Authors:  Michelle J Groome; Lee Fairlie; Julie Morrison; Alan Fix; Anthonet Koen; Maysseb Masenya; Lisa Jose; Shabir A Madhi; Nicola Page; Monica McNeal; Len Dally; Iksung Cho; Maureen Power; Jorge Flores; Stanley Cryz
Journal:  Lancet Infect Dis       Date:  2020-04-03       Impact factor: 25.071

5.  Rotavirus symptomatic infection among unvaccinated and vaccinated children in Valencia, Spain.

Authors:  Raúl Pérez-Ortín; Cristina Santiso-Bellón; Susana Vila-Vicent; Noelia Carmona-Vicente; Jesús Rodríguez-Díaz; Javier Buesa
Journal:  BMC Infect Dis       Date:  2019-11-27       Impact factor: 3.090

6.  National stakeholder preferences for next-generation rotavirus vaccines: Results from a six-country study.

Authors:  Jessica Price; Jessica Mooney; Carolyn Bain; John Tanko Bawa; Nikki Gurley; Amresh Kumar; Guwani Liyanage; Rouden Esau Mkisi; Chris Odero; Karim Seck; Evan Simpson; William P Hausdorff
Journal:  Vaccine       Date:  2021-12-02       Impact factor: 3.641

7.  The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease.

Authors:  Roger I Glass; Jacqueline E Tate; Baoming Jiang; Umesh Parashar
Journal:  J Infect Dis       Date:  2021-09-30       Impact factor: 5.226

8.  Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine.

Authors:  Sung-Sil Moon; Marly Richter-Roche; Theresa K Resch; Yuhuan Wang; Kimberly R Foytich; Houping Wang; Bernardo A Mainou; Winston Pewin; Jeongwoo Lee; Sebastien Henry; Devin V McAllister; Baoming Jiang
Journal:  NPJ Vaccines       Date:  2022-02-28       Impact factor: 7.344

9.  Genetic characterization of two G8P[8] rotavirus strains isolated in Guangzhou, China, in 2020/21: evidence of genome reassortment.

Authors:  Si-Jie Wang; Li-Na Chen; Song-Mei Wang; Hong-Lu Zhou; Chao Qiu; Baoming Jiang; Tian-Yi Qiu; Sheng-Li Chen; Lorenz von Seidlein; Xuan-Yi Wang
Journal:  BMC Infect Dis       Date:  2022-06-28       Impact factor: 3.667

10.  Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial.

Authors:  Firdausi Qadri; Marjahan Akhtar; Taufiqur R Bhuiyan; Mohiul I Chowdhury; Tasnuva Ahmed; Tanzeem A Rafique; Arifuzzaman Khan; Sadia I A Rahman; Farhana Khanam; Anna Lundgren; Gudrun Wiklund; Joanna Kaim; Madeleine Löfstrand; Nils Carlin; A Louis Bourgeois; Nicole Maier; Alan Fix; Thomas Wierzba; Richard I Walker; Ann-Mari Svennerholm
Journal:  Lancet Infect Dis       Date:  2019-11-19       Impact factor: 25.071

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.